Modality
Degrader
MOA
BiTE
Target
FcRn
Pathway
Neuroinflam
SMA
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
May 2021
→ Feb 2030
Phase 1Current
NCT08421285
1,844 pts·SMA
2021-05→2030-02·Not yet recruiting
1,844 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-093.9y awayPh2 Data· SMA
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1/2
Not yet…
Catalysts
Ph2 Data
2030-02-09 · 3.9y away
SMA
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08421285 | Phase 1/2 | SMA | Not yet recr... | 1844 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| ITC-879 | Intra-Cellular | Approved | FcRn |